<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563446</url>
  </required_header>
  <id_info>
    <org_study_id>KWC/EX/05-041</org_study_id>
    <secondary_id>HARECCTR0500029</secondary_id>
    <nct_id>NCT00563446</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia</brief_title>
  <official_title>Conversion From Once Weekly Recombinant Human Erythropoietin to Once Monthly Darbepoetin Alfa for the Treatment of Renal Anemia in Continuous Ambulatory Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kirin Pharmaceutical (Asia) CO., LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      Anaemia is a common consequence of chronic renal failure. Darbepoetin alfa is a unique
      erythropoietic protein that stimulates erythropoiesis by the same mechanism as endogenous
      erythropietin and conventional recombinant human erythropoietin (rHuEPO). Darbepoetin alfa
      has been shown to have a serum half-life 3-fold longer than that of rHuEPO, which allows
      dosing at extended intervals and less frequent injection.

      The objective is to evaluate the efficacy and safety of darbepoetin alfa therapy given at an
      extended once monthly dosing interval in the treatment of renal anaemia in continuous
      ambulatory peritoneal dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Over 6 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Anemia</condition>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Peritoneal Dialysis, Continuous Ambulatory</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients on continuous ambulatory peritoneal dialysis

          -  Patients receiving subcutaneous recombinant human erythropoietin (rHuEPO)

          -  Patients with haemoglobin level ?10 g/dL and remain stable for the past 3 months while
             receiving rHuEPO

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Severe congestive heart failure (NYHA class III or IV)

          -  Grand mal epilepsy

          -  Any kind of blood loss causing Fe depletion

          -  Presence of infection, either acute or chronic, or inflammatory conditions within 3
             months preceding the study

          -  Malignancy

          -  Aluminum toxicity

          -  Severe hyperparathyroidism with marrow fibrosis or osteitis fibrosa _ PTH &gt; 20 times
             of normal

          -  Vitamin B12 or folate deficiency _ MCV &gt; 100fL

          -  Haemolysis

          -  Marrow dysfunction e.g. aplastic anaemia, myelodysplastic syndrome, multiple myeloma,
             etc

          -  Thalassaemia major, intermediate or minor, or red cell enzyme defects

          -  Blood transfusion within 3 months preceding the study

          -  Pregnancy or lactating mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Samuel KS Fung, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Medicine &amp; Geriatrics, Princess Margaret Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ekg.org.hk/HAREC-CTR/RegistryDisplay2.jsp?HARECID=HARECCTR0500029</url>
    <description>HAREC Clinical Trial Registry</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>June 14, 2011</last_update_submitted>
  <last_update_submitted_qc>June 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2011</last_update_posted>
  <keyword>Anemia</keyword>
  <keyword>End-stage renal failure</keyword>
  <keyword>Continuous ambulatory peritoneal dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

